Clinical Trial Update: A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating camrelizumab in combination with docetaxel and S-1 as adjuvant therapy for stage III gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• DOCETAXEL (DOCETAXEL)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: RenJi Hospital | Conditions: Gastric Cancer Stage III | Phase 2 | Status: UNKNOWN